These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 9609603)

  • 1. Principles of current adult HIV pharmacotherapy.
    Landor M
    Ann Allergy Asthma Immunol; 1998 May; 80(5):363-7; quiz 367-8. PubMed ID: 9609603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical issues regarding the use of antiretroviral therapy for HIV infection.
    Deeks SG
    West J Med; 1998 Feb; 168(2):133-9. PubMed ID: 9499754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV suppression and risk of drug resistance mutations.
    Phillips AN; Loveday C; Johnson MA
    AIDS; 1998 Oct; 12(14):1930. PubMed ID: 9792396
    [No Abstract]   [Full Text] [Related]  

  • 6. HIV-1 DNA and RNA kinetics in primary HIV infection.
    Lillo F; Grasso M; Lodini S; Capiluppi B; Lazzarin A; Tambussi G
    J Biol Regul Homeost Agents; 2002; 16(1):49-52. PubMed ID: 12003174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [New biological monitoring of HIV infection].
    Morand-Joubert L
    Rev Prat; 1998 Mar; 48(5):472-7. PubMed ID: 9781107
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunomodulatory effects of antiretroviral chemotherapy.
    Schooley RT
    J Biol Regul Homeost Agents; 1995; 9(3):110-3. PubMed ID: 8782019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.
    Smith PF; Ogundele A; Forrest A; Wilton J; Salzwedel K; Doto J; Allaway GP; Martin DE
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3574-81. PubMed ID: 17638699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV eradication theory meets reality.
    TreatmentUpdate; 1999 May; 11(3):3. PubMed ID: 11366779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [HIV infection. Virus resistance: development and prevention].
    Link R; Miller V; Fätkenheuer G; Manegold C; Harrer T
    Med Monatsschr Pharm; 1999 Mar; 22(3):86-8. PubMed ID: 10223868
    [No Abstract]   [Full Text] [Related]  

  • 12. HIV type 1 integrase inhibitors: from basic research to clinical implications.
    Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M
    AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporating drug-resistance measurements into the clinical management of HIV-1 infection.
    Zolopa AR
    J Infect Dis; 2006 Sep; 194 Suppl 1():S59-64. PubMed ID: 16921474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term suppression of HIV replication in patients with sustained benefit on zidovudine monotherapy.
    Gómez-Cano M; Soriano V; Pérez-Olmeda M; Machuca A; Rodríguez-Rosado R; Valencia E; Moreno V; Gutiérrez M; González-Lahoz J
    AIDS; 1998 May; 12(8):964-6. PubMed ID: 9631158
    [No Abstract]   [Full Text] [Related]  

  • 15. [Saving on drugs, reducing side-effects. Treatment interruptions benefit acute and chronic HIV infected patients].
    Jäger H
    MMW Fortschr Med; 2002 Apr; 144 Suppl 1():8-11. PubMed ID: 12043085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotypic resistance tests for the clinical management of patients with primary HIV infection.
    Narciso P; Lazzarin A
    Scand J Infect Dis Suppl; 2003; 106():66-70. PubMed ID: 15000588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological characterization of patients treated early is able to control HIV-1 replication after multiple cycles of structured therapy interruption.
    Rozera G; Abbate I; D'Offizi G; Corpolongo A; Narciso P; Vlassi C; Martini F; Calcaterra S; Capobianchi MR
    J Med Virol; 2007 Aug; 79(8):1047-54. PubMed ID: 17597482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnosis and virologic monitoring of HIV infection].
    Rouzioux C; Chaix ML
    Rev Prat; 1999 Oct; 49(16):1747-9. PubMed ID: 10578604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
    Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF;
    Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects].
    Marcello A; Giacca M
    Pathologica; 2000 Aug; 92(4):291-3. PubMed ID: 11029891
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.